Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial

Open access
Tang, Yaling, Shah, Hetal, Bueno Junior, Carlos Roberto, Sun, Xiuqin, Mitri, Joanna, Sambataro, Maria, Sambado, Luisa, Gerstein, Hertzel C., Fonseca, Vivian, Doria, Alessandro, Pop-Busui, Rodica · 2021 · Diabetes Care

Abstract

OBJECTIVE: The effects of preventive interventions on cardiovascular autonomic neuropathy (CAN) remain unclear. We examined the effect of intensively treating traditional risk factors for CAN, including hyperglycemia, hypertension, and dyslipidemia, in individuals with type 2 diabetes (T2D) and high cardiovascular risk participating in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. RESEARCH DESIGN AND METHODS: CAN was defined as heart rate variability indices below the fifth percentile of the normal distribution. Of 10,251 ACCORD participants, 71% (n = 7,275) had a CAN evaluation at study entry and at least once after randomization. The effects of intensive interventions on CAN were analyzed among these subjects through generalized linear mixed models. RESULTS: As compared with standard intervention, intensive glucose treatment reduced CAN risk by 16% (odds ratio [OR] 0.84, 95% CI 0.75–0.94, P = 0.003)—an effect driven by individuals without cardiovascular disease (CVD) at baseline (OR 0.73, 95% CI 0.63–0.85, P < 0.0001) rather than those with CVD (OR 1.10, 95% CI 0.91–1.34, P = 0.34) (Pinteraction = 0.001). Intensive blood pressure (BP) intervention decreased CAN risk by 25% (OR 0.75, 95% CI 0.63–0.89, P = 0.001), especially in patients ≥65 years old (OR 0.66, 95% CI 0.49–0.88, P = 0.005) (Pinteraction = 0.05). Fenofibrate did not have a significant effect on CAN (OR 0.91, 95% CI 0.78–1.07, P = 0.26). CONCLUSIONS: These data confirm a beneficial effect of intensive glycemic therapy and demonstrate, for the first time, a similar benefit of intensive BP control on CAN in T2D. A negative CVD history identifies T2D patients who especially benefit from intensive glycemic control for CAN prevention.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc20-1842

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Cited by

See all 68

Metadata

Authors
Tang, Y., Shah, H., Bueno Junior, C. R., Sun, X., Mitri, J., Sambataro, M., Sambado, L., Gerstein, H. C., Fonseca, V., Doria, A., & Pop-Busui, R.
Affiliations
  • Joslin Diabetes Center (US)
  • Research Division, Joslin Diabetes Center, Boston, MA
  • Ca' Foncello Hospital (IT)
  • Population Health Research Institute (CA)
  • Tulane University (US)
  • Division of Metabolism, Endocrinology & Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
Corresponding author
Doria, Alessandro
Venue
Diabetes Care
Published
2020-11-03
Volume
44
Issue
1
Pages
164-173
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W3095717227
Cited by
60
References
35
Citations by year
2026: 4 · 2025: 15 · 2024: 11 · 2023: 10 · 2022: 14 · 2021: 6
FWCI
4.64
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Iacocca Foundation (Mary K. Iacocca Fellowship)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK107956-01, U01 DK119083)
  • JDRF (DK36836)
  • National Heart, Lung, and Blood Institute (N01-HC-95178, N01-HC-95179, N01-HC-95180, N01-HC-95181, N01-HC-95182, N01-HC-95183, N01-HC-95184, IAA-Y1-HC-9035, IAA-Y1-HC-1010)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
cardiac autonomic neuropathy, type 2 diabetes, tight glycemic control, intensive blood pressure control, fenofibrate, heart rate variability, ACCORD trial, cardiovascular risk, hypertension, dyslipidemia, older adults
MeSH terms
Aged, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Fenofibrate, Risk Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. https://app.cochat.ai/papers/10.2337/dc20-1842
The paper
Tang, Y., Shah, H., Bueno Junior, C. R., Sun, X., Mitri, J., Sambataro, M., Sambado, L., Gerstein, H. C., Fonseca, V., Doria, A., & Pop-Busui, R. (2021). Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. Diabetes Care. https://doi.org/10.2337/dc20-1842

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.